NovoCure

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. 

CEO
Frank Leonard
CEOFrank Leonard
Employees
1,605
Employees1,605
Headquarters
St. Helier, Jersey
HeadquartersSt. Helier, Jersey
Founded
2000
Founded2000
Employees
1,605
Employees1,605

NVCR Key Statistics

Market cap
1.83B
Market cap1.83B
Price-Earnings ratio
-12.44
Price-Earnings ratio-12.44
Dividend yield
Dividend yield
Average volume
1.74M
Average volume1.74M
High today
$16.54
High today$16.54
Low today
$15.12
Low today$15.12
Open price
$15.43
Open price$15.43
Volume
1.04M
Volume1.04M
52 Week high
$20.06
52 Week high$20.06
52 Week low
$9.82
52 Week low$9.82

Stock Snapshot

As of today, NovoCure(NVCR) shares are valued at $16.04. The company's market cap stands at 1.83B, with a P/E ratio of -12.44.

On 2026-05-01, NovoCure(NVCR) stock moved within a range of $15.12 to $16.54. With shares now at $16.04, the stock is trading +6.1% above its intraday low and -3.0% below the session's peak.

Trading volume for NovoCure(NVCR) stock has reached 1.04M, versus its average volume of 1.74M.

The stock's 52-week range extends from a low of $9.82 to a high of $20.06.

The stock's 52-week range extends from a low of $9.82 to a high of $20.06.

NVCR News

The Motley Fool 19h
NovoCure Q1 2026 Earnings Transcript

Image source: The Motley Fool. Thursday, Apr. 30, 2026 at 8 a.m. ET Call participants Executive Chairman — William Doyle Chief Executive Officer — Frank Leonar...

NovoCure Q1 2026 Earnings Transcript
Seeking Alpha 1d
Novocure jumps after raising FY26 sales outlook, Q1 revenue beat

NovoCure (NVCR) shares surged nearly 22% on Thursday after the oncology company posted first-quarter revenue well above Wall Street estimates and raised its ann...

Novocure jumps after raising FY26 sales outlook, Q1 revenue beat
TipRanks 1d
Novocure reports Q1 EPS (62c), consensus (51c)

Reports 1Q revenue $174.055M, consensus $167.77M. “This was a very strong start to the year for Novocure (NVCR) and we are pleased with the progress made across...

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
25%
Sell
0%

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.